Reading OVID? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OVID free→Reading OVID? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OVID free→QuarterlyIQ Insights · OVID
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 29, 2026, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) approved, effective as of June 15, 2026, an increase in the size of the Board and, upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), the appointment of Anna Greka, M.D., Ph.D., as a Class…
Results of Operations and Financial Condition. On May 12, 2026, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing business updates and first quarter 2026 financial results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934…
Other Events. On April 17, 2026, the Series A Warrants (the “Series A Warrants”) issued by Ovid Therapeutics Inc. (the “Company”) in connection with its October 2025 private placement expired. The aggregate number of common shares underlying the Series A Warrants was 38,481,325, and investors elected to exercise the warrants into 33,597,860 shares of the Company’s common stock for $1.40 per share and 4,883,464 pre-funded warrants for $1.399 per share, resulting in gross proceeds to the Compan…
Results of Operations and Financial Condition. On March 18, 2026, the Company issued a press release announcing new OV329 data and indication expansion, Phase 1 clearance for OV4071, and fourth quarter and full year 2025 financial results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Secti…
Unregistered Sales of Equity Securities. The information contained in
Entry into a Material Definitive Agreement. Securities Purchase Agreement On March 17, 2026, Ovid Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of 19,154,321 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $2.01 per share and, in lieu of Common Stock, p…
Results of Operations and Financial Condition. On November 12, 2025, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing a planned leadership succession, business updates and third quarter 2025 financial results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 11, 2025, the Company’s Board of Directors appointed Margaret “Meg” Alexander, the Company’s President and Chief Operating Officer, as Chief Executive Officer of the Company and as a Class II member of the Company’s Board of Directors (the “Board”), effective January 1, 2026 (the “Effective Date”). Ms. Alexander succeeds Dr. Jeremy M. L…
Unregistered Sales of Equity Securities. The information contained in
Entry into a Material Definitive Agreement. Securities Purchase Agreement On October 2, 2025, Ovid Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of (i) 57,722 shares of its Series B convertible preferred stock, par value $0.001 per share (the “Series B Preferred Stock”), (ii) Series A warrants (the “Series A Warran…
Results of Operations and Financial Condition. On August 13, 2025, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing business updates and second quarter 2025 financial results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed on a Current Report on Form 8-K filed by the Company on February 13, 2025, the Company received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) on February 10, 2025 notifying the Company that the average closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per sh…
Results of Operations and Financial Condition. On May 13, 2025, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Business Update, First Quarter 2025 Financial Results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…
Results of Operations and Financial Condition. On March 11, 2025, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Business Updates and Fourth Quarter and Full Year 2024 Financial Results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exc…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 1, 2025, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) increased the size of the Board from five to six directors and appointed Stelios Papadopoulos, Ph.D., as a Class I director of the Company, with his term expiring at the Company’s 2027 annual meeting of stockholders. Dr. Papadopoulos was appointed as a…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the last 31 consecutive trading days (the “Notice…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.